CD34-TK75 transduced donor lymphocytes

CD34-TK75 transduced donor lymphocytes is an adoptive cell therapy consisting of allogeneic donor T cells genetically modified with a retroviral vector (often the SFG vector). The modification introduces two key components: a truncated human CD34 cell surface marker, which allows for the ex vivo selection and enrichment of transduced cells, and the Herpes Simplex Virus Thymidine Kinase (HSV-TK) suicide gene. This therapy is primarily developed for patients with relapsed hematologic malignancies following an allogeneic hematopoietic stem cell transplant. The infused donor T cells are intended to mediate a graft-versus-leukemia (GVL) effect to eliminate residual cancer cells. The 'suicide gene' system serves as a safety switch; if the patient develops severe or life-threatening graft-versus-host disease (GVHD), the administration of ganciclovir—which is converted into a toxic metabolite by the HSV-TK enzyme—selectively eliminates the modified donor T cells, thereby controlling the GVHD.

Other names

CD34-TK75 transduced T cellsCD-34-TK75 transduced T cellsCD 34-TK75 transduced T cellsHSV-TK/CD34 transduced donor lymphocytesGenetically modified donor lymphocytes